Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer-Reference-Cited by-同舟云学术

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

Published:2016-10-12 Issue:46 Volume:7 Page:75013-75022
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Thomsen Maria¹²,Kersten Christian³,Sorbye Halfdan⁴,Skovlund Eva⁵,Glimelius Bengt⁶,Pfeiffer Per⁷,Johansen Julia S.⁸,Kure Elin H.⁹,Ikdahl Tone¹⁰,Tveit Kjell Magne¹²¹¹,Christoffersen Thoralf¹²,Guren Tormod Kyrre¹¹¹

Affiliation:

1. Department of Oncology, Oslo University Hospital, Oslo, Norway

2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

3. Department of Oncology, Southern Hospital Trust, Kristiansand, Norway

4. Department of Oncology, Haukeland University Hospital, University of Bergen, Bergen, Norway

5. Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway

6. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

7. Department of Oncology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

8. Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

9. Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

10. Akershus University Hospital, Nordbyhagen, Norway

11. K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway

12. Department of Pharmacology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program;Clinical Colorectal Cancer;2024-06

2. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial;British Journal of Cancer;2024-04-25

3. Interleukin-6-Positive Immune Cells as a Possible New Immunologic Marker Associated With the Colorectal Cancer Prognosis;Applied Immunohistochemistry & Molecular Morphology;2024-04-22

4. Robotic-assisted surgery for left-sided colon and rectal resections is associated with reduction in the postoperative surgical stress response and improved short-term outcomes: a cohort study;Surgical Endoscopy;2024-03-18

5. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer;Targeted Oncology;2024-01